Group items tagged

Sun Pharmaceutical Industries, India's largest drugmaker by revenue, reported a better-than-expected 5.2 per cent rise in third-quarter profit on Tuesday, driven by higher sales of its specialty drugs. The company, known for its consumer healthcare products such as Revital vitamins and pain relief medicine Volini, said it earned a consolidated net profit of 21.66 billion rupees ($265.23 million) in three months ended Dec. 31, up from 20.59 billion rupees last year. Analysts, on average, had expected the company to report a profit of 21.26 billion rupees, according to Refinitiv IBES data. Total revenue from operations climbed nearly 14 per cent to 112.41 billion rupees. Input costs rose 8.5 per cent. Drug sales in India rose 7.1 per cent to 33.92 billion rupees, whereas sales in the United States climbed 16.6 per cent to 34.66 billion rupees, with each of the two regions accounting for 31 per cent of the company's total consolidated sales. The company, founded in 1983, makes over-the-counter medications, anti-retrovirals and active pharmaceutical ingredients for chronic and acute treatments.

In recent years, there has been an increased focus on the importance of health. People are looking for ways to improve their health and live a longer, more productive life. There are many different places that people can go to work on their health, but some are better than others. Here is a list of the top six places to work on your health. 1) MEDICAL SPA A medical spa is a place where people can go to improve their health. medical spas offer a variety of services, including skin care, laser hair removal, and body contouring. They also offer a variety of medical treatments, such as laser surgery and Botox injections. Medical spas offer a number of benefits to their patients. First, they offer a wide variety of services that can help people improve their health. Second, they offer a number of medical treatments that can help people address specific health concerns. Third, they offer a relaxing environment where people can come to improve their health and wellbeing. No matter if you're looking for a medical spa in Alexandria, VA, New York, or any other state, they can be a great place to work on your health. Plus, if you're looking for a place to get health insurance, they can also help you with that.

Drug addiction poses a serious challenge since it impacts one's physical and mental health. However, the good news is that individuals who complete a drug rehabilitation program can overcome this problem. If you are interested in providing rehab services, there are a couple of things you should know. Read on to learn how to operate a rehabilitation clinic flawlessly. KNOW THE NEEDS OF YOUR CLIENTS The main purpose of drug rehab is to help different people overcome addictions. It is designed to heal the body and mind from the negative effects of addiction. It also teaches the affected individuals to learn to live without using substances. Therefore, your first step is to conduct a comprehensive assessment of each client to formulate a personalized treatment plan. Everyone has unique needs in their recovery journey. Your rehab program can start with detox which is designed to rid the body of substances, although it does not treat addiction. The person affected undergoes different therapies during treatment. Therapy helps them deal with the issues that cause substance abuse and teach them healthier ways of life. Various therapies will be applied throughout the entire treatment process. Therefore, you must choose a suitable therapy for each individual. For instance, motivational interviewing and cognitive behavioral therapy are the most common.

The National Institute for Health and Care Excellence (NICE) has recommended faricimab as treatment option for adults with wet age-related macular degeneration or diabetic macular oedema. Thousands of people in England could benefit from the recommendation of a new drug that helps to treat two leading causes of sight loss and visual impairment. Faricimab is administered as an eye injection and is being recommended as an option for treating some adults with wet age-related macular degeneration (AMD) or with diabetic macular oedema (DMO). In the key clinical trials, aflibercept, another eye injection drug used to treat AMD and DMO, was administered every 8 weeks, while faricimab dosing, based on assessments of the disease activity, allowed for an interval of up to 16 weeks between doses, and was found to be equally effective. Up to 300,000 people in England with wet age-related macular degeneration (AMD) could be eligible to receive faricimab as part of their treatment alongside just over 28,000 people with diabetic macular oedema.

The National Institute for Health and Care Excellence (NICE) has recommended pembrolizumab in combination with chemotherapy (paclitaxel or nab-paclitaxel) which is said to benefit people with triple negative breast cancer. Clinical trial evidence shows that, compared with paclitaxel, pembrolizumab combination increases how long people have before their cancer gets worse and how long they live. NICE already recommends atezolizumab in combination with chemotherapy for untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer. Atezolizumab combination is recommended by NICE for people with IC equal to or greater than 1%. "This means that some people who can't have atezolizumab combination could be eligible for pembrolizumab combination," said NICE. NICE's independent appraisal committee also agreed that the pembrolizumab combination meets the higher cost-effectiveness threshold for life-extending treatments for people with a short life expectancy. Given by injection every 3 weeks, pembrolizumab (also called Keytruda and made by Merck Sharp and Dohme) is a type of immunotherapy that specifically targets triple negative breast cancer. It works by blocking the activity of a protein known as PD-L1 which is produced in larger amounts on cancerous cells than normal cells. By blocking PD-L1 it helps the person's own immune cells to attack the cancer.

GlaxoSmithKline and Sanofi said on Wednesday (December 15) they expect data from late-stage clinical trials of its booster dose of their Covid-19 vaccine candidate in the first quarter, instead of this year, another delay for the potential shot. The news came as two companies said preliminary data from trials showed the single-dose booster provided strong immune responses. They added that they need more time to test the booster on more people who have not been infected by the virus before they can submit data to regulators. The Phase III trial for the recombinant adjuvanted Covid-19 vaccine recruited most participants in the third quarter, coinciding with a significant increase in the number of people infected globally due to the Delta variant, it said. "To provide the necessary data to regulatory authorities for the booster vaccine submission, the trial will continue to accrue the number of events needed for analysis, with results expected in Q1, 2022." No safety concerns were identified. This is the latest delay for the vaccine's development, putting the companies further behind rivals in the race for Covid-19 shots.

The NHS on Thursday (May 5) said it has rolled out the arthritis drug baricitinib for seriously ill Covid patients. The Recovery trial, conducted by the NHS and University of Oxford, found that 13 per cent fewer severely ill patients died of Covid when treated with the drug compared to existing treatment options. Typically used to treat arthritis to reduce pain and inflammation, baricitinib can now be given to hospitalised Covid patients in addition to current treatments, and clinical studies show that this can provide benefits on top of existing treatment. The NHS has led the rollout of Covid medicines, from the discovery of dexamethasone as the world's first effective treatment, to the first vaccination outside of a clinical trial in December 2020. The NHS said baricitinib works by reducing inflammation caused by Covid-19 by blocking signals to the immune system that are causing it to attack the body.

In response to the concerning surge in youth vaping, the UK government in January announced its decision to ban disposable vapes as a measure to safeguard the health of children. Prime Minister Rishi Sunak stated that while the long-term impacts of vaping were uncertain, the nicotine present in these products can be highly addictive. Therefore, he emphasised that "marketing vapes to children is not acceptable." Now, there's a stronger reason to crack down on vape sales as a new study has revealed that vaping or the use of e-cigarettes may increase the risk of developing heart failure. The study, which involved 175,000 adults in the United States, found that those who use e-cigarettes were 19 per cent more likely to develop heart failure over a four-year period. Dr Yakubu Bene-Alhasan, lead author of the study, from MedStar Health in Baltimore, underscored that an increasing number of studies are linking e-cigarettes with harmful effects, suggesting vaping "might not be as safe as previously thought." With further research, Dr Bene-Alhasan's team plans to uncover "a lot more about the potential health consequences and improve the information out to the public."

With 118 new cases confirmed by the UK Health Security Agency (UKHSA), the total number of measles cases reported in England since 1 October 2023 has gone up to 465. According to the latest data published by the agency, West Midlands continues to see a disproportionately high rate of infections, with a sharp rise in case numbers over the last six weeks, mainly driven by cases in Birmingham. In England, there were 17 laboratory-confirmed measles cases in October, 42 in November, 161 in December, 240 in January 2024. Five more cases were confirmed last week, according to the measles statistics updated by UKHSA on 8 February. More than 70 per cent (329 of 465) of total confirmed cases were reported from the West Midlands, 13 per cent (62 of 465) from London, seven per cent (32 of 465) in Yorkshire and The Humber, and the remaining cases from other regions of England.

Reena Mehta, consultant pharmacist in the Critical Care team at NHS King's College Hospital, has been announced as chair of the Learning Division for the Intensive Care Society. Mehta took up the post with effect from 8th April, and is the first pharmacist to hold the role of Chair of the Learning Division within the Society. "It is a privilege to be part of the Society and support its life-saving work to enhance our understanding of critical illness and deliver better care to patients," "The intensive care community is made up of multiple professions, each playing a vital role within the critical care team, and I am extremely proud to be the first pharmacist appointed to this important role." In her role as chair of the Learning Division, Mehta will oversee the content of the Society's study days and be responsible for exploring new opportunities for the Intensive Care Society to provide training for our multi professional intensive care community.

The Royal College of Nursing (RCN) has expressed "extreme disappointment" that the UK government offered new pay to NHS consultants, while nursing pay deal remain disputed. RCN General Secretary and Chief Executive Pat Cullen has written to new Health Secretary Victoria Atkins demanding fresh negotiations regarding this year's pay deal, and requested an urgent meeting to discuss their dispute. Pat warned that more than 100,000 RCN members in England voted for continued strike action in June, as they feel undervalued. "The government has now shown it has the political will to negotiate on pay reform for some of the highest earners in the NHS in contrast to our members who received the lowest pay rise in the public sector," she wrote in the letter. NHS nursing staff in England was awarded a five per cent pay rise 2023/24, but the union argued that it is not enough to keep up with inflation.

The Department of Health and Social Care (DHSC) has published the full text of the 2024 voluntary scheme for branded medicines pricing, access and growth (VPAG). The 2024 VPAG agreement text sets out the detailed terms of the agreement reached between DHSC, NHS England and the Association of the British Pharmaceutical Industry (ABPI) to support patient access to medicines, the financial sustainability of the NHS and the UK life sciences sector. The new voluntary scheme will come into force on 1 January 2024, following expiry of the 2019 Voluntary Scheme and shall remain in force for a period of five years, until 31 December 2028. Manufacturers or suppliers of branded medicines to the NHS have been given time till 15 January 2024 to decide whether to join the new 2024 Voluntary Scheme, or default to the updated Statutory Scheme.

The UK Health Security Agency (UKHSA) has warned that there has been a continued increase in cases of whooping cough (pertussis) across England since the start of this year. According to new data published by the agency on Thursday (7 March), 553 new cases of whooping cough were confirmed in January alone, compared with 858 cases for the whole of last year (2023). The country is witnessing a surge in whooping cough cases after a prolonged period of low case numbers, attributed to restrictions and reduced social interaction during the COVID-19 pandemic. England recorded the highest number of whooping cough cases in 2016, recording 5,949 cases. As the ongoing rise coincides with a steady decline in the vaccination rates among pregnant women and children, UKHSA has strongly encouraged mums-to-be to get the maternal pertussis vaccine so that their young baby is protected against this serious disease.

The Joint Committee on Vaccination and Immunisation (JCVI) has advised booster vaccination to be offered this autumn (2023) for those at higher risk of severe Covid-19 in its interim advice to government on the coronavirus (COVID-19) vaccination programme for 2023. The JCVI also advised that for a smaller group of people, such as those who are older and those who are immunosuppressed, an extra booster vaccine dose in the spring should also be planned for. Professor Wei Shen Lim, Chair of Covid-19 vaccination on the JCVI, said: "The Covid-19 vaccination programme continues to reduce severe disease across the population, while helping to protect the NHS. That is why we have advised planning for further booster vaccines for persons at higher risk of serious illness through an autumn booster programme later this year. We will very shortly also provide final advice on a spring booster programme for those at greatest risk."

The Pharmacists' Defence Association (PDA) has welcomed the government's defeat in the House of Lords on the Strikes (Minimum Service Levels) Bill. It believes that the proposed Bill, if enacted, would allow the government to dictate minimum levels of service during times of industrial action, enabling employers to name specific employees that they require in work. Those employees could then face losing their jobs if they failed to turn up to work on that day. Trade unions could also be fined if they did not force those named individuals to go to work. PDA director, Paul Day said, "This Bill should be of real concern to pharmacists and other health professionals. The idea of their employer being able to effectively conscript them to work or face the sack does not feel like a positive employment relations environment." The House of Lords has voted for key amendments to the Bill to prevent unions from being required to force workers to comply. This also prevents workers from being forced to work or face the sack and allows for greater consultation and Parliamentary scrutiny on the proposals which the Westminster government is trying to implement. The House of Commons will now be required to vote on the amendments over the next few weeks. Whilst the House of Lords amendments are likely to be defeated, it shows the degree of opposition there is to this Bill.

An alliance of companies has pledged to ensure equitable access to vaccines and treatments for pandemics, as the friction around intellectual property rights for Covid-19 interventions between the pharmaceutical industry and developing nations endures. At the heart of the plan is a commitment to set aside part of the production of vaccines and treatments upfront for vulnerable populations in low-income countries when the next pandemic arises, given how fragmented access to Covid tools has left many populations unprotected. In order to do better next time - and without knowing which companies will develop the first drugs and vaccines for the next pandemic - having the industry collectively make this commitment is potentially transformative, said Thomas Cueni, head of the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA). The pledge, called the Berlin Declaration, was made on July 19 by members of the global pharmaceutical industry group that include many of the companies involved in developing Covid interventions, such as AstraZeneca, GSK, Moderna, Pfizer and Merck. The declaration is not legally binding. However, if a company that signed on reneges on its vow, it would face grave consequences in the court of public opinion, said Cueni.

The Department of Health and Social Care (DHSC) has issued a medicine supply notification for Temazepam 10mg and 20mg tablets. "Temazepam 10mg and 20mg tablets are in limited supply until w/c 5th December 2022. Alternative benzodiazepines and non-benzodiazepine hypnotics remain available and will be able to support increased demand," said DHSC. Temazepam 10mg/5ml oral solution remains available but cannot support an uplift in demand. DHSC suggested: "Where the above options are not suitable, unlicensed supplies of temazepam 10mg tablets may be sourced, lead times vary." The department confirmed that Target Healthcare, a specialist importers, have confirmed they can source unlicensed Temazepam 10mg tablets. "If there is currently no listing on dm+d for the imported product for prescribers to select using their prescribing systems an EPS prescription for unlicensed Temazepam 10mg tablets cannot be issued."

The Pharmacists' Defence Association (PDA) has reiterated its call for all pharmacists working at Boots to join the PDA Union to support the collective voice of the profession within the company. It said this would enable PDA to send direct communications to pharmacists working at Boots and keep them up to date with key matters impacting their work life. Currently, the association uses the company communication channels to cascade key information to the non-member pharmacists, however, it fears such measures can be disrupted by management. Besides, having more member pharmacists at Boots would strengthen their "negotiating power", PDA said.

The Pharmacists' Defence Association (PDA) has undertaken an additional survey of pharmacists employed in the NHS, before deciding to hold their first-ever ballot for industrial action. The PDA has more than 7,000 NHS-employed pharmacists in membership and the union is actively considering balloting those members regarding strike action. The association said: "The experience of some other unions has shown that the government's restrictive rules, designed to make it difficult for working people to lawfully take industrial action, means trade unions should test members' strength of feeling before balloting." "Trade unions are not only forced to rely upon postal ballots, but for lawful industrial action to be taken, the result must also meet three tests- at least 50% of eligible voters must vote; at least 40% of eligible voters must vote 'yes' and a majority of votes must be for 'yes'." The association is asking members in England, Northern Ireland and, Wales to show if their collective wish, insignificant enough strength, is for strike action. PDA has emailed the survey to all its members in the NHS in the three nations and will close on Tuesday 3 January.

A groundbreaking research project has revealed that the public is urging the government to prioritise primary and community care over hospitals. The study also found a strong public willingness to pay higher taxes to enhance NHS services. The Health Foundation and Ipsos UK conducted the research, combining nationwide polling with in-depth public deliberative workshops. These workshops, held in King's Lynn, Leeds, and London, constitute one of the most comprehensive public consultations about the future of the NHS in England. The study published on 16 May underscores the public's desire for a redistribution of NHS resources. If the NHS budget remains unchanged, 60 per cent of those polled believe the government should focus on improving access to community-based services like general practice and dentistry.